Posted by Michael Wonder on 02 Jul 2020
ICER publishes white paper on alternative policies for drug and vaccine pricing during a pandemic, announces cross-stakeholder discussion series
2 July 2020 - The Institute for Clinical and Economic Review today published a white paper to inform public and policy maker discussion of “Alternative Policies for Pricing Novel Vaccines and Drug Therapies for COVID-19.”
To complement the white paper, ICER will host a three-part online colloquium series featuring leading health policy and industry experts from around the country who will debate the advantages and disadvantages of many different potential approaches to developing and pricing medicines during a pandemic.
